Medifast Announces Third Quarter 2026 Financial Results
Medifast reported Q3 2026 revenue of $72.0 million, down 19.4% year-over-year, with a GAAP net loss of $17.5 million ($1.57 per share) versus a $2.3 million loss a year ago. Active earning coaches fell 47.7% to 10,200 on continued client-acquisition pressure from GLP-1 medication adoption, though revenue per coach rose 54.1% to $7,064 and non-GAAP adjusted loss narrowed to $2.1 million ($0.19 per share). The Catalyst Restructuring drove $15.4 million of charges, inflating GAAP losses while adjusted SG&A fell 16.0%; the balance sheet holds $172.5 million in cash and investments with no debt.
Key figures
- Revenue
- 72048000
- Guidance
- Q4 2026 revenue $55M-$75M and income per share $0.00-$0.25; FY2026 revenue $280M-$300M, GAAP loss per share $1.80-$2.05, non-GAAP loss per share $0.45-$0.70; FY2026 Adjusted EBITDA ex-interest income $10M-$14M
- Revenue Yoy
- -19.4%
- Debt
- 0
- Gross margin
- 69.5%
- Adjusted ebitda
- 362000
- Cash and investments
- 172500000
- Adjusted gross margin
- 71.7%
- Active earning coaches
- 10200
- Active earning coaches yoy
- -47.7%
- Adjusted ebitda ex interest
- 1870000
- Catalyst restructuring charges
- 15406000
- Revenue per active earning coach
- 7064
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.